Armistice Capital’s Pacira BioSciences PCRX Stock Holding History

Armistice Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,892,000	Closed	-$73.1M	–	247
2022 Q4	$73.1M	Buy	1,892,000 +300,000	+19%	+$14.6M	1.27%	20
2022 Q3	$84.7M	Buy	1,592,000 +1,000,000	+169%	+$55.6M	1.47%	15
2022 Q2	$34.5K	Buy	592,000 +68,000	+13%	+$4.45M	0.6%	44
2022 Q1	$40M	Sell	524,000 -788,000	-60%	-$52.5M	0.77%	39
2021 Q4	$78.9M	Buy	1,312,000 +376,000	+40%	+$20.7M	1.29%	15
2021 Q3	$52.4M	Buy	+936,000	New	+$53.9M	0.89%	27
2019 Q2	–	Sell	-1,072,000	Closed	-$40.8M	–	78
2019 Q1	$40.8M	Buy	+1,072,000	New	+$41.8M	2.23%	10
2018 Q2	–	Sell	-726,671	Closed	-$22.6M	–	83
2018 Q1	$22.6M	Buy	726,671 +398,671	+122%	+$14.2M	1.73%	25
2017 Q4	$15M	Buy	328,000 +40,000	+14%	+$1.59M	1.49%	21
2017 Q3	$10.8M	Buy	+288,000	New	+$11.6M	1.27%	28
2017 Q1	–	Sell	-400,000	Closed	-$12.9M	–	54
2016 Q4	$12.9M	Buy	400,000 +132,000	+49%	+$4.4M	3.06%	5
2016 Q3	$9.17M	Buy	+268,000	New	+$10.5M	2.94%	7

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Armistice Capital's PCRX Position: Q1 2023 in Review

Armistice Capital sold out of Pacira BioSciences (PCRX) in Q1 2023, closing a stake of 1,892,000 shares — an estimated $73.1M sold.

Armistice Capital first reported a position in PCRX in Q3 2016 and held it in 12 quarters. The position peaked at $84.7M in Q3 2022. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

Armistice Capital reported no remaining Pacira BioSciences position as of Q1 2023 after selling out during the quarter.
Armistice Capital sold 1,892,000 Pacira BioSciences shares in Q1 2023, an estimated $73.1M.
Armistice Capital first reported a position in Pacira BioSciences in Q3 2016 and held it in 12 quarters.
Armistice Capital's Pacira BioSciences position peaked at $84.7M in Q3 2022.
267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on Armistice Capital's 13F filing for Q1 2023, filed 15 May 2023.